SUSPECT ADVERSE REACTION REPORT

NI-Tolmar-TLM-2025-05030

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year			Day	Month	Year	
DAPH	NICARAGUA	12	Nov	2016	8	Female	19	Dec	2024	

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Gain of 6 kg in 2 months (Weight gain (10047896), Weight increased (10047899))
(/May/2025 -) - Not Recovered/Not Resolved/Ongoing
2) 8-year-old female patient being treated with the drug Eligard 22.5 mg for the indication Central Precocious Puberty (Off label use in unapproved indication (10084345), Off label use (10053762))
(19/Dec/2024 -) - Not Recovered/Not Resolved/Ongoing

Cont..

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☐ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(Unknown)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)

1) (22.5 milligram(s), 1 in 3 Month)

16. ROUTE(S) OF ADMINISTRATION

1) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Central Precocious Puberty [10073186 - Central precocious puberty]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
1) (19/Dec/2024 - ongoing)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) CENTRAL PRECOCIOUS PUBERTY (10073186, Central precocious puberty) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
Anjan.Chatterjee@tolmar.comand+1--9702124900

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
☐ YES ☐ NO	NI-Tolmar-TLM-2025-05030
24c. DATE RECEIVED BY MANUFACTURER: 24/Jul/2025	24d. REPORT SOURCE: ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL
DATE OF THIS REPORT: 31/Jul/2025	25a. REPORT TYPE: ☑ INITIAL ☐ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This study report from Nicaragua was received by Adium via Patient Support Programme (Reference number: NI-ADIUM-NI-0060-20250724 (0)) on 24-Jul-2025 from a consumer (non-healthcare professional) regarding a child, 08-year-old female patient who experienced a non-serious event of ''Gain of 6 kg in 2 months" (Weight increased) and "8-year-old female patient being treated with the drug Eligard 22.5 mg for the indication Central Precocious Puberty" (off label use) during Eligard (leuprolide acetate) 22.5 mg therapy for precocious puberty. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 25-Jul-2025.

The patient's medical history was unknown and current condition included precocious puberty.

Concomitant medication was unknown.

On 19-Dec-2024, the patient began receiving Eligard 22.5 mg every 3 months, via subcutaneous route, for precocious puberty and had off-label use (Lot numbers and Expiration dates were not provided).

On an unknown date in May-2025, the patient had 6 kg weight gain in 2 months. No further details were provided.

Corrective treatment included diet for weight gain.

Relevant lab test:
On an unknown date: Weight: Gain of 6 kg in 2 months (Ref. range: Not provided)

Action taken with Eligard in response to the events was dose not changed. De-challenge and re-challenge were not applicable.

The outcome of weight increased and off label use was not resolved.

The reporter did not assess the seriousness of weight increased and off label use.

The reporter did not provide the causality of off label use in relationship to Eligard and Eligard unspecified device.

The reporter provided the causality of weight increased in relationship to Eligard and Eligard unspecified device as related.

No further query was raised.

Listedness:
Off label use>Eligard>Unlisted as per CCDS>07-Nov-2024
Off label use>Eligard>Unlisted as per USPI>Feb-2025
Off label use>Eligard unspecified device>Unlisted as per USPI>Feb-2025
Off label use>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Weight increased>Eligard>listed as per CCDS>07-Nov-2024
Weight increased>Eligard>unlisted as per USPI>Feb-2025
Weight increased>Eligard unspecified device>unlisted as per USPI>Feb-2025
Weight increased>Eligard>listed as per Canadian monograph>02-Apr-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This is regarding a child 8-year-old female patient who had off label use (8-year-old female patient being treated with the drug Eligard 22.5 mg for the indication Central Precocious Puberty) and weight increased (Gain of 6 kg in 2 mont), during Eligard (leuprolide acetate) 22.5 mg therapy for precocious puberty. Tolmar assessed the events as non-serious since they did not meet the ICH seriousness criteria and are not IME events. The event off label use was considered as not related to Eligard as the event occurred with the product and not due to drug. Off label use is assessed as not related to device component of Eligard. Event weight increased was assessed as related to Eligard (drug) considering the pharmacological profile of drug and not related to device component of Eligard.

Additional Information (Continuation...)

Lab Result :

Test Name	Test Date	Test Result	Normal Value
WEIGHT GAIN	/May/2025		

Test Result (Code) / Result Unstructured Data (free text) :

1) Test Name: WEIGHT GAIN

Continuation Sheet for CIOMS report

Result Unstructured Data (free text) : Gain of 6 kg in 2 months
Test Date: /May/2025

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug : Eligard® (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Daily Dose : (22.5 milligram(s), 1 in 3 Month)
Route of Admin : 1) Subcutaneous
Indications : 1) Central Precocious Puberty [10073186 - Central precocious puberty]
Therapy Dates : 1) From : 19/Dec/2024 To :Continuing
Action(s) Taken With Drug : Dose not changed

Causality

1) Gain of 6 kg in 2 months (Weight gain - 10047896, Weight increased - 10047899)
Causality as per reporter : Related
Causality as per Mfr : Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) 8-year-old female patient being treated with the drug Eligard 22.5 mg for the indication Central Precocious Puberty (Off label use in unapproved indication - 10084345, Off label use - 10053762)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Gain of 6 kg in 2 months
CORE Labeled
2) 8-year-old female patient being treated with the drug Eligard 22.5 mg for the indication Central Precocious Puberty
CORE UnLabeled

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Indications : 1) Central Precocious Puberty [10073186 - Central precocious puberty]
Action(s) Taken With Drug : Not applicable

Causality

1) Gain of 6 kg in 2 months (Weight gain - 10047896, Weight increased - 10047899)
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) 8-year-old female patient being treated with the drug Eligard 22.5 mg for the indication Central Precocious Puberty (Off label use in unapproved indication - 10084345, Off label use - 10053762)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Gain of 6 kg in 2 months
CORE
2) 8-year-old female patient being treated with the drug Eligard 22.5 mg for the indication Central Precocious Puberty
CORE